Celltrion USA signs agreement with Express Scripts, providing access to autoimmune disease therapy for millions of patients.
Celltrion USA has signed an agreement with Express Scripts, a leading pharmacy benefit manager, providing access to its therapy for autoimmune diseases, including the first FDA-approved subcutaneous infliximab, ZYMFENTRA. This agreement opens up an important pathway for treatment access for millions of patients with chronic diseases. The partnership covers more than 100 million people in health plans.
April 29, 2024
4 Articles